Genmab A/S Sponsored ADR (GMAB)
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB
Alliancebernstein L.P. boosted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 2.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,953,913 shares of the company's stock after acquiring an additional 291,538 shares during the quarter. Alliancebernstein
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Is the Options Market Predicting a Spike in Genmab Stock?
Investors need to pay close attention to GMAB stock based on the movements in the options market lately.
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Genmab: AI Partnership And Clinical Data Fuel Growth
Genmab is transitioning from a royalty-driven licensor to an innovation powerhouse with a robust, proprietary pipeline. GMAB delivered 21% revenue growth and 52% operating profit growth, supported by $3.4B in cash and strong operating leverage. Epkinly and Rina-S, with positive clinical data and full or majority ownership, underpin GMAB's multi-billion dollar peak sales potential.
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Presentation Benjamin Jackson Jefferies LLC, Research Division Good to see you all here. Welcome to day 3 of the Jefferies London Healthcare Conference.
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2025 Earnings Call November 6, 2025 12:00 PM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental Medicines Brad Bailey Anthony Pagano - Executive VP & CFO Judith Klimovsky - Executive VP & Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Xian Deng - UBS Investment Bank, Research Division Qize Ding - Rothschild & Co Redburn, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Victor Floch - BNP Paribas, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Charlie Haywood - BofA Securities, Research Division Presentation Operator Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call.
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Genmab A/S (GMAB) M&A Call Transcript
Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental Medicines Anthony Pagano - Executive VP & CFO Judith Klimovsky - Executive VP & Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Qize Ding - Rothschild & Co Redburn, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Sebastiaan van der Schoot Presentation Operator Hello to Genmab's conference call regarding its proposed acquisition of Merus.
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-commercialized drugs EPKINLY and Tivdak. The company is transitioning from a royalty-based model to a diversified commercial portfolio, supported by a $2.9 billion cash reserve.
